Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient

被引：2
|
作者：
Ghosn, Marwan [1 ]
Dagher, Alain [1 ]
El-Karak, Fadi [1 ]
机构：
[1] St Joseph Univ, Dept Hematol Oncol, Fac Med, 894 Blvd Alfred Naccache,Bldg Sehanoui,5th Floor, Beirut, Lebanon
来源：
JOURNAL OF BIOMEDICAL RESEARCH | 2015年 / 29卷 / 05期
关键词：
prostate-specific antigen; doubling time; prostate cancer; cabazitaxel; docetaxel;
D O I：
10.7555/JBR.28.20130148
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy. The patient was monitored by prostate-specific antigen doubling time and prostate-specific antigen absolute value. The prostate-specific antigen doubling time was found to be a good response predictor in the patient.
引用
收藏
页码：420 / 422
页数：3
相关论文
共 50 条
  • [1] Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient
    Marwan Ghosn
    Alain Dagher
    Fadi El-Karak
    TheJournalofBiomedicalResearch, 2015, 29 (05) : 420 - 422
  • [2] Issues with the Use of Prostate-Specific Antigen as a Surrogate End Point in Hormone-Resistant Prostate Cancer
    Newling, Don W. W.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (01) : 13 - 19
  • [3] Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer
    Loberg, RD
    Fielhauer, JR
    Pienta, BA
    Dresden, S
    Christmas, P
    Kalikin, LM
    Olson, KB
    Pienta, KJ
    UROLOGY, 2003, 62 (6B) : 128 - 133
  • [4] THE PROGNOSTIC-SIGNIFICANCE OF PROSTATE SPECIFIC ANTIGEN IN METASTATIC HORMONE-RESISTANT PROSTATE-CANCER
    FOSSA, SD
    WAEHRE, H
    PAUS, E
    BRITISH JOURNAL OF CANCER, 1992, 66 (01) : 181 - 184
  • [5] Prostate-specific antigen response patterns during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer
    Kanao, Kent
    Ito, Toshiki
    Takahara, Kiyoshi
    Ando, Ryosuke
    Yasui, Takahiro
    Shiroki, Ryoichi
    Miyake, Hideaki
    Sumitomo, Makoto
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (11) : 1043 - 1048
  • [6] Prostate-specific antigen doubling time in metastatic castration-resistant prostate cancer: a clinically useful prognostic factor
    Colloca, G.
    Guarneri, D.
    Addamo, G.
    Venturino, A.
    Coccorullo, Z.
    Ratti, R.
    Campora, E.
    EJC SUPPLEMENTS, 2009, 7 (04): : 14 - 14
  • [7] Prostate-specific antigen doubling time as a prognostic marker in prostate cancer
    James A Eastham
    Nature Clinical Practice Urology, 2005, 2 : 482 - 491
  • [8] Prostate-specific antigen doubling time as a prognostic marker in prostate cancer
    Eastham, JA
    NATURE CLINICAL PRACTICE UROLOGY, 2005, 2 (10): : 482 - 491
  • [9] Outcome of patients with hormone-refractory prostate cancer: Prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen
    Tomioka, Susumu
    Shimbo, Masashi
    Amiya, Yoshiyasu
    Nakatsu, Hiroomi
    Murakami, Shino
    Shimazaki, Jun
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (01) : 36 - 42
  • [10] Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer
    Semeniuk, Ross C.
    Venner, Peter M.
    North, Scott
    UROLOGY, 2006, 68 (03) : 565 - 569
12345